Latest / Pharmacy Podcast Network / the Symptomatic Podcast Review Panel | Pharmacy Podcast Network
Transcript
- 0:00Speaker 1: Hey, it's Lauren brace Pacheco back with Season three of Symptomatic,
- 0:05Speaker 1: a medical mystery podcast. This season, we're investigating brand new
- 0:08Speaker 1: cases and even revisiting old friends, piecing together the truly
- 0:13Speaker 1: baffling symptoms, and revealing how the quest from medical answers
- 0:17Speaker 1: transforms the lives of everyday people. This is Symptomatic. Listen
- 0:22Speaker 1: to Symptomatic on America's number one podcast network iHeart. Open
- 0:26Speaker 1: your free iHeart app and search symptomatic and start listening.
- 0:34Speaker 2: Thanks for listening to the Pharmacy Podcast Network.
- 0:45Speaker 3: Hey, welcome to the Pharmacy Podcast Network.
- 0:48Speaker 2: My name's Todd.
- 0:49Speaker 3: You're a founder of the Pharmacy Podcast Network, and you
- 0:53Speaker 3: can see, oh it's this side, My camera's weird.
- 0:56Speaker 2: I am the RX pod father launch.
- 0:58Speaker 3: The first podcast for the farm profession in two thousand
- 1:01Speaker 3: and nine, and I did it because they didn't know
- 1:04Speaker 3: anything about pharmacy.
- 1:06Speaker 2: That's literally the truth.
- 1:07Speaker 3: I kind of knew a little bit about pharmacy, but
- 1:10Speaker 3: I knew that my life was going to stay in
- 1:14Speaker 3: a section of healthcare that I was passionate about. And
- 1:17Speaker 3: pharmacists have done things to medicine, into healthcare and to
- 1:21Speaker 3: treatment that I never ever would have known when I
- 1:25Speaker 3: entered in two thousand and four, twenty years ago getting old.
- 1:29Speaker 3: So when I pulled together business people and experts and
- 1:35Speaker 3: people that are dialing into pharmacogenomics and when we start
- 1:39Speaker 3: really thinking about how can pharmacists participate, we had to
- 1:43Speaker 3: bring them into the Symptomatic podcast review panel because this
- 1:49Speaker 3: is fun.
- 1:50Speaker 2: I have had the honor.
- 1:53Speaker 3: To help out with the iHeartMedia channel, which is run
- 1:57Speaker 3: by a team of passionate people that want pharmacy. I'm sorry,
- 2:02Speaker 3: I want patient stories told with intelligence and positioning and description,
- 2:09Speaker 3: and so Symptomatic really makes it fun because it's it's
- 2:12Speaker 3: a mystery.
- 2:13Speaker 2: I mean, you don't you don't know, and listen, I'm
- 2:15Speaker 2: the consumer.
- 2:16Speaker 3: I'm the one that's coming at this non clinically, and
- 2:19Speaker 3: to have clinical friends that you can send something to
- 2:22Speaker 3: and be like can you guess this before the end
- 2:25Speaker 3: of the podcast, where you're able to really dial into
- 2:29Speaker 3: what that means as a clinical leader or somebody that's
- 2:33Speaker 3: been in business that understands something in healthcare. So I
- 2:37Speaker 3: want to welcome my panel, starting with a podcaster who
- 2:42Speaker 3: reinvented pharmacoache genomics and what that meant for network. We
- 2:47Speaker 3: reset that podcast Hard. About two years into it, Becky
- 2:51Speaker 3: actually shamed me. She's like, this is not good. We
- 2:54Speaker 3: need to reform the doctor Becky Winslow welcome, Hi.
- 3:00Speaker 4: Everybody, thanks for having me. God's right. We made some
- 3:04Speaker 4: significant changes.
- 3:07Speaker 2: Did all right.
- 3:09Speaker 3: The Pain Guy, this guy is amazing in my life.
- 3:12Speaker 3: He lived close to me. He's down in West Virginia.
- 3:15Speaker 3: He is certified in mass.
- 3:20Speaker 5: Mass destruction mitigation or something like that. That hits the fan.
- 3:25Speaker 6: We've got a certificate. Don't worry. We having one for everything.
- 3:29Speaker 3: That got him some attention from powers that be that
- 3:32Speaker 3: wanted to know what that meant. But the Pain Guy,
- 3:35Speaker 3: my friend, doctor Mark Garrow fully welcome.
- 3:38Speaker 2: It's great to have you here.
- 3:40Speaker 6: Thank you, Todd Caster.
- 3:41Speaker 5: Always a pleasure, you know, representing as Pain Guy here,
- 3:46Speaker 5: you know, thoroughly, always enjoying grabbing a mic, respecting the mic,
- 3:50Speaker 5: not given opinions, but given the facts, given the stories.
- 3:54Speaker 5: You know, this idea of you know, symptomatic overall, it's
- 3:57Speaker 5: storytelling and that's that's where everybody, this panel, that's where
- 4:01Speaker 5: it's at. You know, we can throw some facts at you,
- 4:04Speaker 5: probably won't remember them.
- 4:06Speaker 7: Tell a story.
- 4:08Speaker 5: It's ingrained in here, you know, that's that's really where
- 4:11Speaker 5: it's at.
- 4:12Speaker 3: Absolutely, thank you Tomorrow, such a special person in the
- 4:18Speaker 3: network and what you represent and how you've brought a
- 4:22Speaker 3: cutting edge or bleeding edge study and moving forward, what
- 4:27Speaker 3: pharmacist impact is going to have on healthcare and people's lives.
- 4:30Speaker 3: But then nutrition and being able to die, dial into
- 4:33Speaker 3: what we're eating and how fascinating that is and how
- 4:36Speaker 3: that's an exploding trend. So I like being on the edge.
- 4:38Speaker 3: But introducing to our audience tonight.
- 4:41Speaker 8: Hi everyone tomorrow, Yes, I specially I'm a pharmacist specializing
- 4:45Speaker 8: in nutri genomics. I took a little pivot to not
- 4:50Speaker 8: just focus on medications, but also focus on our genetics
- 4:54Speaker 8: and how the food we eat, the environment that we
- 4:56Speaker 8: put ourselves in affects our genes. And interestingly, I'm able
- 5:02Speaker 8: to merge both the pharmaceutical aspect and the genomic aspect
- 5:07Speaker 8: with the clients.
- 5:08Speaker 2: That I that I see, Yeah, it's going to make
- 5:10Speaker 2: a lot of sense.
- 5:11Speaker 3: In tonight's discussion with symptomatic Steven Beckman from my this
- 5:17Speaker 3: is where the studio is, he's not here, he's actually
- 5:19Speaker 3: out and about because he's always traveling all over the places.
- 5:22Speaker 3: You know, you're all pharma, but a client, a friend,
- 5:25Speaker 3: a fellow Brown's villion. Is that what we call them,
- 5:28Speaker 3: a Brown's villion. It's so good to have you here.
- 5:33Speaker 3: I appreciate you being here tonight.
- 5:35Speaker 9: Well, it's a pleasure to be part of this panel
- 5:38Speaker 9: and a part of these really smart people that you've
- 5:40Speaker 9: invited the I'm the guy that spent most of my
- 5:44Speaker 9: career on the on the pharmaceutical manufacturing side. But I
- 5:47Speaker 9: think we have some really important stories to tell. There's
- 5:51Speaker 9: a lot of misunderstanding as well as a lot of
- 5:53Speaker 9: good understanding of what we do. But most importantly, we're
- 5:57Speaker 9: in the position as the suppliers of the tools and
- 6:00Speaker 9: medicines that we used to do it responsibily, to do
- 6:04Speaker 9: it in a way that insures great patient outcome. And
- 6:08Speaker 9: I'll date myself, but I've been doing this for about
- 6:11Speaker 9: thirty five years. And I walked into it with the
- 6:14Speaker 9: idea that I had three job offers out of school.
- 6:17Speaker 9: One was to sell Coca Cola, one was to sell
- 6:20Speaker 9: Armstrong flooring, and the last one was to a couple
- 6:24Speaker 9: opportunities in the pharmaceutical industry. So I sat down one
- 6:27Speaker 9: night with my father, I said, well, what should I do.
- 6:29Speaker 9: He goes, well, what do you think would mean the most?
- 6:31Speaker 9: I said, well, I think pharmaceuticals might be a good
- 6:33Speaker 9: place where I can do something good, so said, I've
- 6:35Speaker 9: given people diabetes with coca cola. I've spent my career
- 6:39Speaker 9: helping people hopefully derive better outcome through proper choice of
- 6:46Speaker 9: the right medications within their treatment regimen. So it's a
- 6:49Speaker 9: pleasure to be here.
- 6:51Speaker 2: Thank you for being here. I appreciate it, all right,
- 6:54Speaker 2: I'll tell you what.
- 6:55Speaker 3: So if anyone remembers the HBO, one of my most
- 6:58Speaker 3: favorite shows of my entire higher life.
- 7:00Speaker 2: Ever I was addicted to. This show was success.
- 7:04Speaker 3: So if I were to make a show right now,
- 7:06Speaker 3: if you just dropped me three hundred and fifty million
- 7:08Speaker 3: dollars and let's go make a show, I would make
- 7:11Speaker 3: a show that was the opposite of the type of
- 7:13Speaker 3: people that Succession were kind of about where they were,
- 7:16Speaker 3: you know, shystring and trying to get up ahead.
- 7:19Speaker 2: And but Ryan would.
- 7:21Speaker 3: Be the opposite, but it would still be the cool
- 7:25Speaker 3: success strategy.
- 7:27Speaker 7: Mind.
- 7:27Speaker 3: This man's mind is blowing me away. And I met
- 7:30Speaker 3: him on Instagram, and I'm very fortunate that we've that
- 7:34Speaker 3: we met Ryan, and I'm excited here.
- 7:36Speaker 7: Yeah, thanks so much for having me. Like Todd said,
- 7:38Speaker 7: my name is Ryan Paul.
- 7:39Speaker 10: I'm actually a pharmaceutical epidemiologist by trade, but I've spent
- 7:44Speaker 10: most of my career as a serial health apreneur. I
- 7:48Speaker 10: spend most of my time investing in startups and had
- 7:52Speaker 10: the privilege recently to take the helm of an organization
- 7:55Speaker 10: called Mango Health that provides on site pharmacy management for
- 7:58Speaker 10: mental health and addiction treatment facilities, which is a part
- 8:01Speaker 10: of my story. I'll look forward to telling that tonight
- 8:04Speaker 10: as part of our conversation.
- 8:06Speaker 7: So thanks so much Tom for having me.
- 8:08Speaker 10: And no doubt there's some brilliant people on this panel
- 8:11Speaker 10: and I'm excited to have the conversation.
- 8:14Speaker 3: Me to thank you so much. So this is symptomatic.
- 8:18Speaker 3: This is a podcast. It was about something that was
- 8:23Speaker 3: happening in a patient's life that they didn't understand. They
- 8:27Speaker 3: received a headway or an initial diagnosis, they start worrying
- 8:31Speaker 3: about it. So right out of the gate, I'm going
- 8:35Speaker 3: to give my stage of this. I'm the consumer. I
- 8:40Speaker 3: listened to these because I was really interested in understanding
- 8:43Speaker 3: what was being missed. Based on what I understand about
- 8:46Speaker 3: pharmacy and soaked in this for twenty years now, so
- 8:49Speaker 3: I was coming at it from a very sincere perspective. However,
- 8:53Speaker 3: which stalled me was the stress and episode case number nineteen.
- 9:00Speaker 3: It was Josie that I felt that I wasn't able
- 9:04Speaker 3: to understand where to even push them because of how
- 9:10Speaker 3: complex the actual conditions were. As I was listening to
- 9:14Speaker 3: the stress and their voices blah blah blah, so I
- 9:16Speaker 3: started losing track of what I was supposed to be doing.
- 9:18Speaker 3: I was supposed to be listening to these podcasts to
- 9:21Speaker 3: really clean specific grasp, and then the patient pulled me
- 9:24Speaker 3: in and it impacted me and made me start researching
- 9:30Speaker 3: the issues and the the me putting myself in that position.
- 9:34Speaker 3: So right out of the gate, I want to go
- 9:36Speaker 3: to Becky Winslow, Doctor Winslow, I want to kind of
- 9:39Speaker 3: open up with Josie and.
- 9:42Speaker 2: You're feeling and background on it.
- 9:44Speaker 4: Sure, I mean, I think I'll start by saying that
- 9:47Speaker 4: the patients whose stories that we heard, I wish I
- 9:51Speaker 4: could say that they're unique or that this isn't a
- 9:55Speaker 4: common situation where patients struggle to get a an accurate
- 10:00Speaker 4: diagnosis and to get the appropriate treatment. It's not. You know,
- 10:05Speaker 4: we call it practicing medicine because that's what we're doing.
- 10:08Speaker 4: We're practicing medicine. And especially with conditions where the symptoms
- 10:15Speaker 4: are general in nature, not specific or unique to the condition,
- 10:23Speaker 4: doctors have to go through the differential diagnosis process. So
- 10:29Speaker 4: not that these stories are unusual, but you're exactly right.
- 10:33Speaker 4: It can be very challenging as patients try to navigate
- 10:39Speaker 4: the health care system. You know, as a patient myself,
- 10:43Speaker 4: I find it stressful to try to navigate health care.
- 10:48Speaker 4: I can't imagine navigating it not having worked in health
- 10:53Speaker 4: care and knowing the systems and how to maybe get
- 10:58Speaker 4: to the endpointint faster than if I was just outsearching
- 11:03Speaker 4: for answers. So I think for Jose, I think it's
- 11:07Speaker 4: important to recognize that, you know, once he was diagnosed,
- 11:14Speaker 4: once his doctors were able to pinpoint what was wrong,
- 11:18Speaker 4: then they started the trial and error process with the
- 11:21Speaker 4: medications and trying to find a medication that will be
- 11:24Speaker 4: appropriate for him. And although they did not mention medication
- 11:29Speaker 4: names for Jose, I know as a as a pharmacist
- 11:35Speaker 4: that there are certain medications that are used to treat
- 11:38Speaker 4: patients with ibs, and I also know that there is
- 11:42Speaker 4: testing available that helps to make sure that those patients
- 11:48Speaker 4: are experiencing therapeutic outcomes and less or lower rate of
- 11:55Speaker 4: side effects than they have to. So I love the
- 11:59Speaker 4: art the iHeart podcast episode on him, and I would
- 12:03Speaker 4: love to add to the episode, you know, those drug
- 12:08Speaker 4: names and how we can help shorten those patients roads
- 12:12Speaker 4: to recovery. I think that was my biggest Oh my gosh,
- 12:17Speaker 4: I want to jump in there.
- 12:18Speaker 2: And say this.
- 12:20Speaker 3: Absolutely I get that, and I immediately started thinking of
- 12:25Speaker 3: the world of pain and what we experience and how
- 12:29Speaker 3: subjective it is. A five year old in pain versus
- 12:34Speaker 3: a sixty four year old in pain who's gotten used
- 12:37Speaker 3: to living with it is going to rate pain very differently.
- 12:40Speaker 3: So doctor garyfully mark herifully the pain guy. I'm just
- 12:45Speaker 3: glad that you're here talk to me from your perspective
- 12:48Speaker 3: of Josie's case and how pain might, like you know,
- 12:53Speaker 3: influence that.
- 12:55Speaker 5: So, you know, first off, today I appreciate you know,
- 12:58Speaker 5: as a pharmacist, these things are giving us wings, giving
- 13:01Speaker 5: us voices. So I appreciate again and being here, you know,
- 13:06Speaker 5: in listening to these podcasts.
- 13:08Speaker 6: You know, even beyond this case.
- 13:10Speaker 5: It's one of those where you're automating on the edge
- 13:11Speaker 5: of your seat, but for various reasons, it's you know,
- 13:16Speaker 5: you're rooting for the patient, but then as a clinician
- 13:18Speaker 5: is a healthcare professional, as a pharmacystem.
- 13:20Speaker 6: Sitting there like.
- 13:23Speaker 5: Why can't we just and by the way, armchair quarterbacks
- 13:26Speaker 5: rule hindsight is twenty twenty. You know, when you're listening
- 13:30Speaker 5: to a podcast, you're not in an operating room.
- 13:32Speaker 6: I hope maybe not.
- 13:35Speaker 5: I don't know, not a surgeon, just pharmacist, right, But
- 13:41Speaker 5: you know when somebody you got like two options basically
- 13:44Speaker 5: in cases like this, I saw this in multiple episodes
- 13:47Speaker 5: for symptomatic you know, besides being on the edge of
- 13:50Speaker 5: the seat or on the edge of wherever somebody's doing.
- 13:52Speaker 5: Want to listen to a podcast, either have the option
- 13:56Speaker 5: where clinicians are not listening and I mean like sit down, ears, open,
- 14:02Speaker 5: eyes off the screen, stop typing listening, or turns out
- 14:07Speaker 5: it's such a complicated case that no matter how much
- 14:10Speaker 5: you listen, you're gonna need some help, right I I uh,
- 14:14Speaker 5: he's not a philosopher, he's a rapper.
- 14:16Speaker 6: We know him as Vanilla Ice. He said it better
- 14:20Speaker 6: than anyone.
- 14:20Speaker 5: Sorry, guys and gals, anyone on this panel could do stop,
- 14:24Speaker 5: collaborate and listen. It's literally the charge for these.
- 14:27Speaker 6: Podcasts I got. I got the podfather to dance.
- 14:33Speaker 2: I'm thinking now because I literally used to twenty one
- 14:37Speaker 2: dance group things. This was the nineties. People, you stood
- 14:43Speaker 2: up and you showed up. So I was he's on.
- 14:45Speaker 5: Like HGTV these days, I'll still sun my role and
- 14:48Speaker 5: maybe that was last decade.
- 14:49Speaker 6: I don't know, but.
- 14:50Speaker 5: Anyways, you know, going back to it, it's you know,
- 14:52Speaker 5: either not listening, and that's that's easily mitigated by hey,
- 14:55Speaker 5: let's stop and.
- 14:55Speaker 6: Listen and we see that.
- 14:57Speaker 5: You know, you go to an airport, the TSA agent
- 14:59Speaker 5: is typing away and you're like, what could they possibly
- 15:01Speaker 5: be typing the right seven hundred words? It's been ten seconds.
- 15:05Speaker 5: But when we see that in clinical care, it's a
- 15:06Speaker 5: whole other story. So there's that option. But you know,
- 15:09Speaker 5: a lot of these cases that we're listening to, particularly
- 15:11Speaker 5: this one too, you know.
- 15:13Speaker 6: It's it's complicated.
- 15:15Speaker 5: It's it's clinicians realizing and patients alike that you're not
- 15:20Speaker 5: going to talk to one person that probably has the
- 15:22Speaker 5: answer relatively easily, and that's tough. I'm sure we've all
- 15:27Speaker 5: been there as patients as well too, of the oh
- 15:30Speaker 5: my goodness, now we're in the other seat, and that's
- 15:34Speaker 5: a story into itself always. You know, I've had my
- 15:38Speaker 5: kidney stone story during the pandemic and all that. There's
- 15:41Speaker 5: you know, things you don't want to go through.
- 15:42Speaker 6: Particularly with pain. I'll go there, of course where and
- 15:47Speaker 6: sometimes you don't even want to talk about.
- 15:48Speaker 5: It afterwards, like oh, yeah, hey, that was fantastic, five star.
- 15:51Speaker 5: I had a great time. But you can help others
- 15:55Speaker 5: with the stories. And that's what you know, this case,
- 15:58Speaker 5: all the cases on symptomatic are doing where you're helping
- 16:01Speaker 5: other people. The charge of pharmacy, the charge of all
- 16:04Speaker 5: healthcare really, so you know, maybe that's too big picture,
- 16:08Speaker 5: but I wanted to start there.
- 16:09Speaker 2: So that's no, no, that's appreciated.
- 16:12Speaker 3: And then that and I I like that perspective because
- 16:16Speaker 3: pain does play into a lot of things.
- 16:18Speaker 2: So yeah, thank you for that. Tomorrow.
- 16:21Speaker 3: I'm so excited you're here because every time I was
- 16:24Speaker 3: listening to this and we were staging this, and I
- 16:27Speaker 3: reached out to you to ask you if you wanted
- 16:28Speaker 3: to do this, and You're like, heck, yeah, I was
- 16:30Speaker 3: so excited. All right, where does what does nutrition? What
- 16:35Speaker 3: do substances? What does sugar? What does you know avocado?
- 16:40Speaker 7: Like?
- 16:40Speaker 2: What did these substances do to us?
- 16:43Speaker 6: Right?
- 16:44Speaker 3: And so you're bringing a perspective this it's pretty special.
- 16:46Speaker 3: So introduce yourself to our listeners.
- 16:48Speaker 8: Hello, Hello, Yes tomorrow. Doctor Tamar specialize in nutrient genomics,
- 16:53Speaker 8: which is a science of how food affects your genes,
- 16:56Speaker 8: plain and simple.
- 16:57Speaker 2: You know, Uh, one thing that really stood out.
- 17:00Speaker 8: To me first, I want to say before I get
- 17:01Speaker 8: into the genomics part of it with Jose's case is
- 17:07Speaker 8: the support he had from his mother. I couldn't imagine
- 17:10Speaker 8: having to go through that by myself. So it's important
- 17:14Speaker 8: that our patients have an advocate for them or support
- 17:17Speaker 8: system for them. So fortunately Jose had that. When I
- 17:22Speaker 8: was listening to this, what went through my mind was, Oh,
- 17:25Speaker 8: I wonder what kind of genetic variants he has that
- 17:27Speaker 8: could have indicated that he may potentially have irritable bowel syndrome. Now,
- 17:33Speaker 8: nutril genomics is not going to diagnose you with IBS,
- 17:36Speaker 8: but it will highlight some genetic variants that might make
- 17:41Speaker 8: you more prone to inflammatory conditions. So for example, there's
- 17:46Speaker 8: interluken twenty three of receptor, there may be a variant
- 17:50Speaker 8: with that receptor or ATG sixteen L one, which is
- 17:56Speaker 8: autophogy related gene. These two genes actually influenced the immune system.
- 18:02Speaker 2: And inflammation as well.
- 18:04Speaker 8: So I wouldn't be surprised if he had these variants
- 18:08Speaker 8: and they're at all. If you were to do a
- 18:11Speaker 8: YouTube genoment test and it's actually been they've actually been
- 18:14Speaker 8: associated with conditions like all sort of colitis.
- 18:18Speaker 2: It's incredible, And there's the finding there that's dialing into that.
- 18:22Speaker 2: So that's what I'm.
- 18:24Speaker 3: Saying, like, there there's so many situations where patients are
- 18:28Speaker 3: going through something and you have specialists, and you have
- 18:31Speaker 3: the pediatrician, and you have the person that is dialing
- 18:36Speaker 3: into the data or EKG expert or whatever it is.
- 18:40Speaker 3: How many times are they missing out on a pharmacist
- 18:44Speaker 3: Like wait a second, yes, about what's this person going through,
- 18:47Speaker 3: what's this little person going through, what's this senior going through,
- 18:51Speaker 3: what's this person that's experiencing pain going through? And it's
- 18:54Speaker 3: a giving it's giving us an opportunity with symptomatic to
- 18:57Speaker 3: really dial into these cases and and like you said
- 19:01Speaker 3: to war being able to say hold on a second.
- 19:03Speaker 3: There's an extra element to this. It ties back to
- 19:06Speaker 3: the basics of every human being on the face of
- 19:09Speaker 3: the earth, and that its assumption of substances and foods
- 19:13Speaker 3: and whatever it is that literally impact our lives and
- 19:17Speaker 3: people are dial in.
- 19:19Speaker 2: Some people are I mean you are tomorrow.
- 19:21Speaker 3: I want to set up a separate appointment just for
- 19:24Speaker 3: my own help anytime, Todd.
- 19:27Speaker 8: But it's we can't forsake that. It has to be integrative, right,
- 19:31Speaker 8: because you can't just focus on one thing when it
- 19:33Speaker 8: comes to treatment or management of these disease states, or
- 19:36Speaker 8: even diagnosis of these disease states, because these diseases are
- 19:40Speaker 8: so complex. So definitely taking a holistic or integrative approach
- 19:45Speaker 8: to look at a variety of factors.
- 19:47Speaker 2: Yep, excellent, Steve Beckman.
- 19:50Speaker 3: I'll tell you what the You and I come at
- 19:53Speaker 3: things very similar because we have more of a business
- 19:56Speaker 3: background than a clinical background.
- 19:58Speaker 2: But our backgrounds.
- 20:00Speaker 3: Into making sure that our pharmacists, who are the most
- 20:03Speaker 3: trusted healthcare professionals out there in their communities, are getting
- 20:07Speaker 3: what they need. And so I thought, wow, I need
- 20:10Speaker 3: a business guy here to be on my side. Of
- 20:12Speaker 3: the fence because's out there tonight.
- 20:16Speaker 9: Well again, it's a pleasure to be on the podcast
- 20:19Speaker 9: here and with this fine panel.
- 20:20Speaker 11: I think, look.
- 20:21Speaker 9: At you know, in the pharmaceutical industry and how we
- 20:24Speaker 9: delivered drugs that help patient outcome. We've done things the
- 20:28Speaker 9: same way for a long long time, and to be
- 20:31Speaker 9: honest with you, I've been doing it for over thirty
- 20:33Speaker 9: five years, and a lot of the things that we've
- 20:34Speaker 9: done have been wrong. We do a lot of qualitative
- 20:37Speaker 9: research and quantitative research, and a lot of that stays
- 20:41Speaker 9: at the physician level, and what we've lost in that
- 20:45Speaker 9: over many years is that we haven't translated down through
- 20:48Speaker 9: the value chain of healthcare, especially with pharmacists and a patience.
- 20:53Speaker 9: And that's what's great about this platform because at the
- 20:56Speaker 9: end of the day, a lot of times we think
- 20:59Speaker 9: we know what our patient populations wants because we've been
- 21:03Speaker 9: experts in delivering respiratory care in asthma or CRPD or
- 21:07Speaker 9: whatever area you want. But what we forget is, at
- 21:10Speaker 9: the end of the day, the most important thing we
- 21:12Speaker 9: can do is listen, We learn, we think, and then
- 21:18Speaker 9: we act. And that's one of the things that we're
- 21:20Speaker 9: trying to do as an organization is actually listen more
- 21:24Speaker 9: to the end user and kind of work our way
- 21:27Speaker 9: back up the kind of the pathway than down the pathway.
- 21:30Speaker 9: And I think through that we have the ability now
- 21:34Speaker 9: to start really listening to what the real needs are.
- 21:37Speaker 9: And that starts and ends with me with a patient.
- 21:39Speaker 9: That's why I joined this industry is because I wanted
- 21:42Speaker 9: to do something that would help people. And I'm not
- 21:47Speaker 9: a trained scientist or I'm not a physician. I'm just
- 21:51Speaker 9: a caring business guide that wants to do good. So
- 21:54Speaker 9: I think what's great about the platform and listening to
- 21:56Speaker 9: patient stories is that we can now translate in a
- 22:00Speaker 9: different way than we've done before, or we can listen
- 22:03Speaker 9: in a way that we've not done before and then
- 22:05Speaker 9: translate it. And when we do that, I think it
- 22:08Speaker 9: gives us the opportunity to rethink about how we can
- 22:11Speaker 9: deliver better value. And when we think about drugs, you know,
- 22:14Speaker 9: we need to be thinking about patient cohorts under a therapy.
- 22:17Speaker 9: You can't just say somebody has asthma, So everybody has
- 22:20Speaker 9: asthma and the drug use are all Pain is a
- 22:23Speaker 9: big area in our business right now, and you know,
- 22:26Speaker 9: and talking and working with Mark. You know, one of
- 22:27Speaker 9: the great things he's shared and is really impressed upon
- 22:30Speaker 9: me is options in pain are very important. So how
- 22:33Speaker 9: do you navigate those to get it down to the
- 22:35Speaker 9: patient that you can create real outcome. But you can't
- 22:38Speaker 9: really do that if we do if we don't listen
- 22:41Speaker 9: to patient. And we've always getten taken it from the
- 22:44Speaker 9: top down, and we've looked at things like comorbidities and
- 22:48Speaker 9: things like that and try to.
- 22:49Speaker 11: Navigate all that.
- 22:49Speaker 9: But really what we have to understand is we have
- 22:52Speaker 9: to get even more sensitive to to be able to
- 22:56Speaker 9: deliver products that meet the individual needs. And we have
- 22:59Speaker 9: podcor in levothroxin, and we have one of a product
- 23:02Speaker 9: that's unique from a doss form, being a gel cap
- 23:05Speaker 9: versus the tablets, which is the dominant form. Fact, but
- 23:08Speaker 9: a lot of patients have tolerability and an allergic response
- 23:12Speaker 9: to many of the inactives in these levo tablets. Our
- 23:15Speaker 9: product only has four ingredients and doesn't have the same profile. Now,
- 23:19Speaker 9: as a company, we're not trying to go out and
- 23:22Speaker 9: satisfy and convert all patients to our product, but there's
- 23:26Speaker 9: ten percent of those patients that would benefit from that,
- 23:29Speaker 9: and that's what our requirement is if we service the
- 23:33Speaker 9: patients well, the business will take care of itself. And
- 23:35Speaker 9: the best way we service patients. If a patient's not
- 23:38Speaker 9: compliant on a drug and there's an alternative but they
- 23:41Speaker 9: don't know, then how are they going to find it?
- 23:43Speaker 9: And where that starts, and where I believe that really
- 23:46Speaker 9: starts as with a pharmacist, because I believe in all
- 23:48Speaker 9: the work I've done that pharmacists are either tracking because
- 23:52Speaker 9: aren't filling their chronic medication. They realize they're not refilling,
- 23:55Speaker 9: So there's a reason for that. It could be priced,
- 23:57Speaker 9: it could be tolerability, it could be what it is,
- 24:00Speaker 9: or the patients coming to them first in many cases.
- 24:03Speaker 9: And that's where as an organization that we have, we've
- 24:05Speaker 9: actually taken a very different approach to do that bottom up,
- 24:09Speaker 9: not only listen to the patient so forth that we
- 24:11Speaker 9: actually spend more money right now investing in the pharmacist
- 24:14Speaker 9: than we do on any other healthcare provider. I'm not
- 24:17Speaker 9: taking away all the importance of all the healthcare providers.
- 24:21Speaker 9: One health provider that's been probably the most underappreciated my
- 24:26Speaker 9: entire thirty years has been the pharmacist. And that's something
- 24:28Speaker 9: that we need to do more.
- 24:30Speaker 2: Thank you. I appreciate you being here.
- 24:33Speaker 3: I'm excited to have you in this show, Ryan, because
- 24:38Speaker 3: you really come at things four dimensionally from so many
- 24:41Speaker 3: of the conversations that we've had about health. And also
- 24:44Speaker 3: a shout out for you really being a hero and
- 24:48Speaker 3: an assistance to your community in what you went through
- 24:51Speaker 3: with the latest hurricane that came up and just knocked
- 24:55Speaker 3: out Carolina. So I'm just glad you're here.
- 24:59Speaker 2: Thanks Tow.
- 24:59Speaker 7: I appreciate that.
- 25:00Speaker 12: Yeah, Hurricane Helen was a beast, but we prevailed without
- 25:04Speaker 12: a doubt, and we're thankful and grateful to be safe
- 25:07Speaker 12: and sound and be able to have the resources to be.
- 25:12Speaker 10: Of service to our community. So we'll keep after it.
- 25:16Speaker 10: We didn't we didn't go back down to Saint John, right,
- 25:18Speaker 10: we stayed here. So with that said, I'll take it
- 25:23Speaker 10: from kind of a two approach. Number One, I love
- 25:26Speaker 10: symptomatic because it reminds us that the patient is always
- 25:29Speaker 10: at the center of everything that we do.
- 25:31Speaker 11: Right.
- 25:32Speaker 10: So if we can if we can center the patient,
- 25:34Speaker 10: no matter what the conversation is, we're going to end
- 25:37Speaker 10: up in the right place. But as an epidemiologist and
- 25:40Speaker 10: a lot of people don't know even what an epidemiologist is.
- 25:44Speaker 10: As a pharmaceutical epidemiologist, we really study the distribution, determinants
- 25:48Speaker 10: and deterrence of health and disease in populations. Right, So
- 25:53Speaker 10: for us, information is crucial for developing public health strategies,
- 25:57Speaker 10: guiding health care policies, and prioritizing research investments. That I'm
- 26:02Speaker 10: going to hold off on my excitement about the mental
- 26:06Speaker 10: health aspect of IBD and talk about the gut brain
- 26:10Speaker 10: access doctor tomorrow because I want us to talk about that.
- 26:14Speaker 7: But what I wanted to really touch.
- 26:15Speaker 10: On is is that you know, the future is promising
- 26:20Speaker 10: as it relates to genetic research. And so if I
- 26:23Speaker 10: take off the epidemiologist hat and I set that down,
- 26:25Speaker 10: and I put the investor hat on, and I think
- 26:28Speaker 10: about what type of innovation we want to continue to
- 26:33Speaker 10: invest in from a biotech perspective, it really is that
- 26:37Speaker 10: innovation that ultimately centers the patient. And again, the reason
- 26:41Speaker 10: why I love symptomatic and really, quite frankly, the reason
- 26:44Speaker 10: why I love pharmacists. I grew up in a pharmacist family.
- 26:47Speaker 10: My grandfather was a pharmacist. He owned a very large
- 26:50Speaker 10: chain of pharmacies called the apothecary shops. My mom was
- 26:54Speaker 10: a pharmacy tech forum. You know, I grew up walking
- 26:57Speaker 10: in and out of the pharmacy. That what that felt
- 27:01Speaker 10: like home to me, right, So when I started deciding
- 27:05Speaker 10: what I was going to be, when I decided to
- 27:07Speaker 10: be an entrepreneur, I knew it was going to be
- 27:08Speaker 10: an entrepreneur in the pharmacy space. So I'm excited about
- 27:13Speaker 10: what this panel is doing because they're innovating, they're bringing
- 27:16Speaker 10: new ideas to the table, and we're actually able to
- 27:19Speaker 10: help them execute on those ideas. So, whether it's ib D,
- 27:23Speaker 10: whether it's Macromaglia, as we'll talk about in a little bit,
- 27:29Speaker 10: there is hope for healthcare yet in the United States,
- 27:34Speaker 10: and this this panel is a representation of that.
- 27:37Speaker 3: Absolutely absolutely, And thank you for being here, and thank
- 27:42Speaker 3: you all for being here. So I'm excited to kind
- 27:44Speaker 3: of dig into into this next case, and we're going
- 27:49Speaker 3: to come back to Josie too, because I have some
- 27:51Speaker 3: additional questions, but just going to keep the openings for
- 27:54Speaker 3: each of these going. And that was Kelly, And you know,
- 27:58Speaker 3: by this time, I understand to what I was going
- 28:00Speaker 3: after I was understanding on Josie in a relationship with
- 28:05Speaker 3: his mother and what he went through with ibs like
- 28:07Speaker 3: he I couldn't have thought of that as one of
- 28:10Speaker 3: my children, not so much myself, but I started thinking
- 28:13Speaker 3: about my daughters and stuff like that. But then Kelly
- 28:16Speaker 3: came in and she's like, Okay, I don't know what's
- 28:19Speaker 3: going on my weight gain and you know miss sist
- 28:24Speaker 3: of subject to brain surgery and she was it was
- 28:29Speaker 3: just like genetic revelations, and it was like I was like,
- 28:33Speaker 3: this is the one like this is for my pharmacist family.
- 28:37Speaker 3: So starting all right out of it with with Becky
- 28:41Speaker 3: taking away. With regards to Kelly and we you were thinking, yeah.
- 28:45Speaker 4: When I agreed to join you guys, I didn't realize
- 28:48Speaker 4: that one of the episodes was on pharmacogenemics. So as
- 28:53Speaker 4: I'm listening and I'm hearing Kelly's story, you know, I
- 28:57Speaker 4: get goosebumps because the number of people that maybe experiencing
- 29:06Speaker 4: adverse drug events, but that's not what they're recognized as.
- 29:13Speaker 4: In her case, she was diagnosed with acromegally they wanted
- 29:20Speaker 4: to do brain surgery on her. Those are very life altering,
- 29:27Speaker 4: needless to say. And I just wonder because I didn't
- 29:31Speaker 4: hear in her story. Was there a pharmacist that was
- 29:36Speaker 4: involved that understands the genetic basis of adverse events, drug
- 29:43Speaker 4: events and non therapeutic drug outcomes that might have recognized.
- 29:48Speaker 4: You know, it took her seeing her doctor at Mayo Clinic.
- 29:52Speaker 4: And you know Mayo Clinic is very well known for pharmacogenemics.
- 29:55Speaker 4: There's some of the pioneers and some of the godfive
- 30:00Speaker 4: of pharmacoachre No moments came out of Mayo, needless to say,
- 30:03Speaker 4: but you know how many patients every day walked into
- 30:07Speaker 4: their doctor's office describing symptoms of what they think maybe
- 30:13Speaker 4: a new onset condition or advance of the condition they
- 30:18Speaker 4: already had, when it's actually side effects of a medication.
- 30:24Speaker 4: Her side effects were extreme, and it took her a
- 30:28Speaker 4: very long time to get to that answer, to find
- 30:31Speaker 4: out that because she wasn't metabolizing medication appropriately, the medication
- 30:37Speaker 4: was building up in her system and causing these toxicities.
- 30:41Speaker 4: And the class of drugs that I don't remember if
- 30:45Speaker 4: she named them specifically. I believe she said they were
- 30:48Speaker 4: for gastric reflux or heartburn, maybe how she described it,
- 30:53Speaker 4: but her time pump inhibitors are one of the most
- 30:57Speaker 4: commonly prescribed drugs on the MAT and unfortunately, not only
- 31:02Speaker 4: do they get prescribed, but then they don't get de
- 31:05Speaker 4: prescribed after you know, the intended use period. And so
- 31:11Speaker 4: you will see I used to work in long term care.
- 31:14Speaker 4: We would see patients on these medications for years and years.
- 31:21Speaker 4: And you know, we also know that prescribing cascades occur.
- 31:24Speaker 4: So you know along the lines, was the patient describing
- 31:30Speaker 4: aches pains kind of like Kelly, and you know, doctors
- 31:35Speaker 4: were just prescribing more medications to treat those adverse effects.
- 31:40Speaker 4: So that Kelly's case, absolutely, Yeah, I was surprised. I
- 31:46Speaker 4: wasn't expecting it. But it's the story that I tell.
- 31:50Speaker 7: That's that's what I tell.
- 31:52Speaker 2: That's my story.
- 31:53Speaker 4: You know I talk about pharma coachy gnomics. I have
- 31:56Speaker 4: that platform, Okay, help patients get to that information faster.
- 32:04Speaker 3: Yeah, yep, oh wow, I tell you what that opened
- 32:09Speaker 3: up my mind to pharmaco genomics and when I started
- 32:14Speaker 3: learning about that in twenty sixteen, and how that component
- 32:18Speaker 3: of pharmacists leadership is just enormous.
- 32:22Speaker 2: Mark, what about Kelly? What what.
- 32:25Speaker 3: Were you thinking of before you actually realized what it
- 32:29Speaker 3: What the conclusion.
- 32:30Speaker 5: Was so what a case, what a human you know,
- 32:36Speaker 5: let let's humanize these cases. This this podcast certainly symptomatic
- 32:41Speaker 5: does that effectively.
- 32:42Speaker 6: It's very hard to do that.
- 32:45Speaker 5: They do it very well though, when you know, when
- 32:48Speaker 5: thinking through, you know, this isn't like one of those
- 32:50Speaker 5: things like.
- 32:51Speaker 6: Oh is there a fault? Is there whatever?
- 32:53Speaker 12: You know?
- 32:54Speaker 5: Within this panel, I think when being invited, you know,
- 32:58Speaker 5: their natural presumption, Hey, maybe one of our specialties will
- 33:01Speaker 5: come up in cases.
- 33:02Speaker 6: Me I'm like, of course, panel come up. How does
- 33:05Speaker 6: it not come up?
- 33:05Speaker 5: It's literally everywhere that stinks, But it's literally everywhere, so
- 33:11Speaker 5: you know, and I always did Todd you know me best.
- 33:16Speaker 5: You know, I try to inject a little humor and on,
- 33:19Speaker 5: try and cross the line. But when you have these cases,
- 33:22Speaker 5: it's very tricky to be like, hey, let let's stop
- 33:25Speaker 5: and learn here, you know, for the future, for when
- 33:27Speaker 5: the next patient presents with something similar. They'll probably ever
- 33:30Speaker 5: be the same, but it could be similar. And you know,
- 33:34Speaker 5: with that in mind, it's that general idea of do
- 33:38Speaker 5: we want you know, in a world of excel and
- 33:41Speaker 5: spreadsheets and flow charts and how you know, the insurance
- 33:46Speaker 5: side of healthcare has put everything into the clouds like
- 33:50Speaker 5: this one, yes or no, this one or this one
- 33:52Speaker 5: depending on where you go, and all these flow charts,
- 33:55Speaker 5: and that has become the arts of diagnosis and sometimes
- 33:59Speaker 5: treatment as well too. When you know who I want
- 34:02Speaker 5: in the background, you know who I want for Kelly?
- 34:04Speaker 5: Besides folk find folks on this panel. I want Alan
- 34:09Speaker 5: from the Hangover. I'm going to give that a second
- 34:13Speaker 5: or three. Most people have seen the remember in the
- 34:17Speaker 5: movie or seen the meme or picture, whatever you want
- 34:20Speaker 5: to call it.
- 34:20Speaker 6: And it's when he's thinking and all the math is
- 34:23Speaker 6: going through.
- 34:23Speaker 5: He's trying to, you know, do his thing with Blackjack,
- 34:25Speaker 5: but all the numbers, all the things are floating through
- 34:27Speaker 5: his mind. You know what's not floating through his mind
- 34:30Speaker 5: depicted in that scene low charts. It's not ask this,
- 34:34Speaker 5: get yes or no, go to the next thing. It's
- 34:36Speaker 5: there's a human presenting something, talking it through, or even
- 34:40Speaker 5: a chart and you're looking through. You want all the options,
- 34:44Speaker 5: you know, would it have been great if Kelly saw
- 34:46Speaker 5: doctor Becky like at the beginning of the case. Heck,
- 34:50Speaker 5: if it's my mom or me, that's what I want.
- 34:53Speaker 5: I want that pharmacist. She's sitting right there. The rest
- 34:56Speaker 5: of y'all two, And it's then it becomes boring, but
- 35:00Speaker 5: in a good way, in.
- 35:01Speaker 6: A compassionate way, because it's done.
- 35:03Speaker 5: Case over, pharmacist rocket and.
- 35:06Speaker 6: That's what we need.
- 35:08Speaker 11: We need more of.
- 35:09Speaker 6: That like that.
- 35:10Speaker 5: That's I'm sure anyone could piggyback on that one.
- 35:15Speaker 2: Absolutely, and it's true.
- 35:16Speaker 3: It's it's it's a missing it's a missing link because
- 35:19Speaker 3: it's not a natural part of our and get to
- 35:25Speaker 3: the medical record and the physician is like, Okay, what's
- 35:27Speaker 3: my next step? Why aren't you kicking this off to
- 35:30Speaker 3: a pharmacist? Has nothing to do with expensing. It has
- 35:32Speaker 3: to do with dialing into the individual. And that's that's
- 35:36Speaker 3: your whole that's your whole, gig. So talk to us
- 35:38Speaker 3: about Kelly.
- 35:42Speaker 8: Yes, Kelly, Okay, So three things I want to talk
- 35:45Speaker 8: about with Kelly. First, patient advocacy and empowerment. Once she
- 35:51Speaker 8: she advocated for herself to find another solution contact it
- 35:55Speaker 8: wrote the male culinic herself. And then that empowerment she
- 35:58Speaker 8: felt when she as she understood that it was related
- 36:02Speaker 8: to the medications and her genetics, Like you could just
- 36:05Speaker 8: hear it in her voice, like how ether's already happened?
- 36:07Speaker 8: It was like it was happening again, like she was
- 36:09Speaker 8: discovering again. It's so important again patient advocacy. It's important
- 36:14Speaker 8: for them to feel in powered that they can take
- 36:16Speaker 8: action when it comes to their health. The first second thing,
- 36:22Speaker 8: remember she started out talking about migraines since she was
- 36:25Speaker 8: sixteen years old. That's where this all started. Migraine, she
- 36:28Speaker 8: was sixteen years old. It's a family thing. I believe
- 36:30Speaker 8: it's a quote unquote is what she said. So migraines
- 36:34Speaker 8: ran in her family. I'm looking at my notes here.
- 36:37Speaker 8: So it wasn't until she was thirty two years old
- 36:39Speaker 8: after her third pregnancy where she started having heartburn and
- 36:42Speaker 8: then she was.
- 36:43Speaker 6: Put on PPIs.
- 36:45Speaker 8: So from my nutri genomic mind, with my goal to
- 36:50Speaker 8: reduce the need for medications and my clients, I'm thinking
- 36:54Speaker 8: at sixteen years old, they're triggers for those migraines, right,
- 36:59Speaker 8: and later on in life heartburn is also a trigger
- 37:03Speaker 8: for migraines as well, so it probably preceded her migraine,
- 37:08Speaker 8: her migraines coming on when she was older. But knowing
- 37:11Speaker 8: what your triggers are, But then genetically, there are several
- 37:17Speaker 8: factors we can look at as well to determine your
- 37:20Speaker 8: risk of migraines or what might be contributing to your migraines,
- 37:24Speaker 8: and from a neutri genomic perspective, we can then fine
- 37:28Speaker 8: tune your nutrition plan, your lifestyle plan. Inflammation is very
- 37:34Speaker 8: much involved with migraines, detoxification, oxidative stress. We have that
- 37:39Speaker 8: gut health, that gut brain access a relationship again, is
- 37:44Speaker 8: so important when it comes to migraines. A lot of
- 37:48Speaker 8: people don't think about that what's going on in the
- 37:50Speaker 8: gut affects our mind, our brain. So from Nuture's moments perspective,
- 37:55Speaker 8: we can then narrow down the type of foods that
- 37:58Speaker 8: she can avoid and also that she should be on
- 38:01Speaker 8: to help mitigate the effects of those migraines and potentially
- 38:04Speaker 8: never have to be put on PPIs as a result
- 38:07Speaker 8: of gurt.
- 38:09Speaker 12: Yeah.
- 38:09Speaker 3: I want to bring you in, Ryan, because you did
- 38:12Speaker 3: mention this to me next before the show started, and
- 38:17Speaker 3: I want you to kind of jump on what Tomorrow
- 38:20Speaker 3: was talking about and how yeah you're saying.
- 38:23Speaker 10: Well, yeah, doctor Tomorrow is right on, and I imagine
- 38:28Speaker 10: she's right on ten out of ten times. But you know,
- 38:32Speaker 10: I was actually referring to jose right because there was
- 38:36Speaker 10: a specific conversation about mental health, right, and we know.
- 38:41Speaker 7: That there is a.
- 38:44Speaker 10: Lot of issues as it relates to mental health when
- 38:48Speaker 10: you're talking about IBD. But you know, the gut brain,
- 38:52Speaker 10: we're going to jump into the brain access and just
- 38:55Speaker 10: so the audience kind of has an understanding. It's a
- 38:58Speaker 10: bi directional link which were in the central nervous system
- 39:02Speaker 10: and the enters nervous system of the body. Right, So
- 39:05Speaker 10: it is basically what we're putting into our gut is
- 39:09Speaker 10: creating a microbiome in our gut, and that is impacting
- 39:12Speaker 10: the rest of our body, and it is impacting our
- 39:15Speaker 10: mental health.
- 39:16Speaker 11: Right.
- 39:16Speaker 10: Like, so for instance, gluten, gluten is an offender of
- 39:20Speaker 10: mental health. Dairy is an offender of mental health. And
- 39:24Speaker 10: so that's what I was talking about Todd when I
- 39:26Speaker 10: sent you that text, was you know when we when
- 39:29Speaker 10: you know, so from an epithet, you know, and so
- 39:31Speaker 10: like kind of to transition back to like the way
- 39:34Speaker 10: that I see it from an epidemiological perspective, I'm automatically
- 39:39Speaker 10: going to go back to and and to doctor Mark's point,
- 39:43Speaker 10: we don't want.
- 39:44Speaker 7: Right the check the boxes. If this, then this, r this,
- 39:48Speaker 7: then this.
- 39:50Speaker 10: But on the same token to train really great diagnosticians,
- 39:54Speaker 10: they have to they have to start there, right, So
- 39:56Speaker 10: I'm going to ask, what's the prevalence and incidents, what's
- 39:59Speaker 10: age diagnosis, what's the diagnostic delays, what's the impact on
- 40:04Speaker 10: quality of life? There's lots of things from an epidemiological
- 40:07Speaker 10: perspective that we are going to put in quote unquote
- 40:10Speaker 10: boxes and kind of hand.
- 40:11Speaker 7: Off so that the creativity can happen.
- 40:14Speaker 11: Right.
- 40:15Speaker 10: So if there is some paint and a paint brush,
- 40:18Speaker 10: so we can hand it off to the farm d's
- 40:20Speaker 10: of the world, the physicians, so that they can be
- 40:23Speaker 10: the artists and they can start to paint and get
- 40:25Speaker 10: creative about these diagnostic opportunities. I mean, here's the reality
- 40:29Speaker 10: with acromeglia. It's sixty sixty out of one million, sixty
- 40:34Speaker 10: cases out of one million. So the chances of knowing
- 40:39Speaker 10: that in the onset is virtually impossible. Right, So the
- 40:45Speaker 10: question then becomes, what do we have to do knowing
- 40:48Speaker 10: that it seems virtually impossible to make that diag you know,
- 40:51Speaker 10: to make that diagnosis in the beginning. That's where research
- 40:56Speaker 10: scientists like myself have to do a better job with
- 40:59Speaker 10: the information that we're given. So that we can create
- 41:01Speaker 10: some boundaries as it relates to what's happening with the population,
- 41:05Speaker 10: based on region, based on demographics, based on geography, a
- 41:10Speaker 10: slew of things.
- 41:14Speaker 3: Hey, thanks for listening to this review of Symptomatic. This
- 41:18Speaker 3: is a podcast that's done by iHeartRadio their Ruby division.
- 41:23Speaker 3: Please search Symptomatic podcast. It's a medical mystery podcast. We're
- 41:28Speaker 3: going to take a quick break. We'll be right back.
- 41:35Speaker 1: Uncertainty.
- 41:36Speaker 6: I'm not even sure if I could describe it well.
- 41:39Speaker 5: It almost just felt like I was I.
- 41:41Speaker 2: Wasn't living isolation.
- 41:44Speaker 8: I stopped once to the doctor, I stop trying to
- 41:47Speaker 8: find treatments.
- 41:49Speaker 2: Nothing was working.
- 41:50Speaker 1: Breakthrough.
- 41:52Speaker 5: You couldn't imagine that anyone could be alive and have
- 41:56Speaker 5: a mutation in that gene.
- 41:59Speaker 1: I'm Lauren Checko, host of Symptomatic, a medical mystery podcast.
- 42:05Speaker 1: Every episode we investigate the medical mysteries behind someone's truly
- 42:09Speaker 1: baffling symptoms, revealing how the quest for answers transforms the
- 42:13Speaker 1: lives of everyday people. This is symptomatic.
- 42:23Speaker 7: My name, my name.
- 42:24Speaker 2: My name is Kelly Athena And for nineteen years, for fifteen.
- 42:29Speaker 5: Years, over twelve years, I suffered with a mysterious.
- 42:32Speaker 8: Illness, struggled, I struggled with misdiagnoses of a previously undiagnosed disease,
- 42:38Speaker 8: an unknown disease.
- 42:40Speaker 1: Listen on the iHeartRadio app, Apple podcasts, or wherever you
- 42:43Speaker 1: get the stories that matter to you.
- 42:47Speaker 2: Thank you for that.
- 42:48Speaker 3: So Steve and I, you and I share, you know,
- 42:54Speaker 3: viewpoints in some ways, but you're a little deeper than
- 42:56Speaker 3: I am from even a perspective because of your background
- 43:00Speaker 3: into just being in it for so long in pharma.
- 43:02Speaker 3: But I was thinking of this as Hey, if my
- 43:06Speaker 3: daughter was going through this perspective, and how sickening it
- 43:12Speaker 3: would be for me as a parent.
- 43:14Speaker 2: What did you think about Kelly's case.
- 43:17Speaker 9: Well, Kelly's case actually, to take it home personally, really
- 43:22Speaker 9: translated to my own daughter.
- 43:24Speaker 11: I have a daughter's twenty six years.
- 43:26Speaker 9: Old and she was diagnosed at six with migraines and
- 43:33Speaker 9: we have struggled for twenty years. And at first it
- 43:40Speaker 9: was manageable for certain things, and then as she got
- 43:43Speaker 9: into high school, all the comments, especially made by Ryan
- 43:48Speaker 9: in terms of the mental health. Part of this is
- 43:51Speaker 9: amazing interplay between the physical and mental. And you know,
- 43:58Speaker 9: when you see we searched out answers everywhere, But we
- 44:02Speaker 9: had a very difficult time, and I think it was
- 44:04Speaker 9: because we didn't really have the balance of that structured
- 44:06Speaker 9: quantitative side and the qualitative side that mark what's happening
- 44:11Speaker 9: at twenty seconds twenty six year old. My daughter is
- 44:13Speaker 9: still not fully functional in today's world, and if we
- 44:20Speaker 9: had the tools, we would be better off. So it's
- 44:26Speaker 9: it's when I've listened to some of these cases, this
- 44:30Speaker 9: one really hit home for me because you know, for me,
- 44:35Speaker 9: what it means is that we still need to do
- 44:36Speaker 9: a better job of doing the quantitative and the and
- 44:39Speaker 9: the functional side that Ryan was talking about. We have
- 44:41Speaker 9: to check the boxes right, but the market point, we've
- 44:44Speaker 9: got to find that better way to bring the patient
- 44:47Speaker 9: into humanity. Because I've lived it with her forever, and
- 44:50Speaker 9: I still don't think I truly appreciate what has struggled.
- 44:54Speaker 9: She has struggled on the pure management of having, you know,
- 44:58Speaker 9: severe migraines two or three times a month, and as.
- 45:02Speaker 11: A result, when she got to college.
- 45:03Speaker 9: She actually tried to commit suicide because it had consumed
- 45:08Speaker 9: her on a mental health perspective. Now spent equal amount
- 45:12Speaker 9: of time trying to solve both sides of this equation
- 45:15Speaker 9: and that only comes the only answer we're going to
- 45:19Speaker 9: get is that we've tried to put all these pieces
- 45:21Speaker 9: to better more effectively, and my goal has been for
- 45:25Speaker 9: the last twenty years is to try to help her
- 45:28Speaker 9: find that outcome and answer. So, you know, nutritional aspects
- 45:34Speaker 9: we haven't really actually gotten to as much, which is
- 45:37Speaker 9: very interesting. So doctor you and I might be having
- 45:39Speaker 9: some more conversations podcast, but we've tried everything else. But
- 45:43Speaker 9: we also took it for more of a traditional approach
- 45:46Speaker 9: and then we went to the non traditional approaches. So
- 45:48Speaker 9: I again, I think we almost did it backwards. We
- 45:51Speaker 9: kind of followed a traditional path and we didn't step
- 45:53Speaker 9: back and actually better evaluate when the time has happened,
- 45:58Speaker 9: when to present, how is presenting, how changing and approach
- 46:01Speaker 9: different ways and when I think about it now, I've
- 46:05Speaker 9: been preparing for this and have a comment.
- 46:08Speaker 11: The one aspect that we also missed.
- 46:10Speaker 9: Out a lot on was the pharmacists input on this process,
- 46:13Speaker 9: and that's been a big regret.
- 46:15Speaker 11: So we've.
- 46:17Speaker 9: Worked with a lot more pharmacists than last year and
- 46:19Speaker 9: she's actually, I'm happy to say, has made some progress
- 46:22Speaker 9: in the last twenty four months to the fact that
- 46:25Speaker 9: she's now gone back to get her master's degree or
- 46:28Speaker 9: almost completed her master's degree. And my hope is that
- 46:33Speaker 9: what has translated into a very difficult start her life
- 46:37Speaker 9: and a feeling of not being to be healthy and
- 46:41Speaker 9: productive is we're getting closer to turning that page to
- 46:45Speaker 9: being a productive part of society. And that will be
- 46:49Speaker 9: probably the greatest accomplishment I will ever winness personally.
- 46:52Speaker 6: To achieve that goal.
- 46:54Speaker 3: That's special. That's special. Thank you for sharing that with us, Steve,
- 46:58Speaker 3: and I appreciate that. Thank you to this panel so far.
- 47:02Speaker 3: This has been dissecting these cases in different perspectives, and
- 47:07Speaker 3: every single one of you have brought something to this
- 47:10Speaker 3: that I never thought of before, and really going deeper
- 47:14Speaker 3: with symptomatic and how many healthcare providers who aren't listening
- 47:18Speaker 3: to this show. If this is the first time you've
- 47:20Speaker 3: ever heard of symptomatic, go to any of your podcast
- 47:24Speaker 3: players and just put in symptomatic.
- 47:27Speaker 2: It'll come right up, guarantee it.
- 47:30Speaker 3: And it's been an addition to my podcast player obviously
- 47:34Speaker 3: because of just catching up and understanding. And I always
- 47:38Speaker 3: listened to a couple of days before we went to
- 47:39Speaker 3: the NASP, which is national Association of Specialty Pharmacy, which
- 47:44Speaker 3: is digging down into rare diseases. And so when I
- 47:48Speaker 3: thought of this next case, which was our case in
- 47:52Speaker 3: Scott was our patient. This one was the most intense
- 47:56Speaker 3: of the three for me because of the fact that
- 47:59Speaker 3: Scott almost died and it was that's the scary way
- 48:04Speaker 3: that gets. So I want to bring in Becky and
- 48:07Speaker 3: just you know, jump right into this one.
- 48:10Speaker 4: Well, I think it's important to bring up the fact
- 48:13Speaker 4: that now with medication, as medications evolve and treatments evolved,
- 48:22Speaker 4: they're going to be more precise. Okay, So medications that
- 48:26Speaker 4: are being introduced into the market now for the most part,
- 48:31Speaker 4: are not general medications or they're not non specific. They're
- 48:36Speaker 4: very precise medications. And I just want to make sure
- 48:39Speaker 4: that we're letting patients know, physicians know that if a
- 48:45Speaker 4: companion diagnostic exists for medications that are new to the market,
- 48:51Speaker 4: that's the perfect scenario because companion diagnostics are required to
- 48:58Speaker 4: determine if a medication and will be effective for a
- 49:01Speaker 4: patient or if it's less likely to cause side effects.
- 49:05Speaker 4: We see these companion diagnostics frequently in oncology. We're starting
- 49:11Speaker 4: to see them more in non oncology settings. But I
- 49:15Speaker 4: think it's very important that we point out this opportunity
- 49:19Speaker 4: that the patient needs to know about, so that the
- 49:23Speaker 4: patient doesn't have to tell the story of I almost
- 49:26Speaker 4: died before I got you know, the help I needed.
- 49:30Speaker 4: And so we're going to be seeing more and more
- 49:35Speaker 4: precision medications designed specifically to treat conditions. And I'm sure
- 49:44Speaker 4: that Ryan can speak on this, you know, as a
- 49:47Speaker 4: scientist and how medications you know, as we research the
- 49:53Speaker 4: variants amongst patients that experience these conditions, and we can
- 49:57Speaker 4: identify the common invariants amongst these patients so that we
- 50:04Speaker 4: can figure out how to treat them precisely. You know,
- 50:07Speaker 4: that is where medicine is headed and being more precise.
- 50:12Speaker 6: I love it.
- 50:13Speaker 2: I love it. Well, you're tagged.
- 50:16Speaker 3: It was.
- 50:18Speaker 2: It's like a big ring.
- 50:20Speaker 11: Yeah.
- 50:20Speaker 10: So I mean, I'll keep it short because this one
- 50:23Speaker 10: can turn into a dissertation because I have I had
- 50:25Speaker 10: this conversation a lot. So Number one, Doctor Becky is
- 50:31Speaker 10: one thousand percent right, that is where medication is going.
- 50:33Speaker 7: But here's the issue with that.
- 50:36Speaker 10: It treats less people, right, the marketplace is smaller, ye,
- 50:40Speaker 10: And so you know, I'll put.
- 50:42Speaker 7: On the investor hat for a second.
- 50:44Speaker 10: I had a conversation today with a biomedical company in
- 50:47Speaker 10: a in an what we call it Alpha group, and
- 50:51Speaker 10: we were having the conversation about how we actually raise
- 50:54Speaker 10: capital for these types of innovations.
- 50:58Speaker 7: Knowing full well that the arc of.
- 51:02Speaker 10: Capital return is far away, and so really what we
- 51:09Speaker 10: need in precision medication? And I think it's it goes
- 51:13Speaker 10: back to is the patient at the center of the motive, right?
- 51:18Speaker 10: Or is profit just the motive? Because quite frankly, I
- 51:21Speaker 10: can just tell you that for many years profit was
- 51:25Speaker 10: my motive.
- 51:26Speaker 7: It was.
- 51:26Speaker 10: It wasn't until some radical, wild things happened in my life,
- 51:30Speaker 10: you know, some really hard, difficult things happened in my
- 51:32Speaker 10: life to where all of a sudden I just viewed
- 51:35Speaker 10: what my calling.
- 51:36Speaker 7: Was very differently.
- 51:38Speaker 10: But we're having difficulty raising capital around precision medication, and
- 51:42Speaker 10: so guess what happens is is that precision medication is
- 51:45Speaker 10: then shelfed and the smaller companies, right, the vcs, the
- 51:52Speaker 10: private equity firms, the companies that are operating with less
- 51:55Speaker 10: than one hundred million in capital. And you think that
- 51:57Speaker 10: that's a lot of money, it's just simply not in
- 51:59Speaker 10: that space. Right, But if we're operating with about one
- 52:02Speaker 10: hundred and eight to one hundred and fifteen million at
- 52:04Speaker 10: any given time, we don't have enough money at a
- 52:07Speaker 10: two percent administrative fee to be able to even walk
- 52:10Speaker 10: through the door from.
- 52:11Speaker 7: A research perspective.
- 52:12Speaker 10: So you have the Eli Lillies, you have the pfizers,
- 52:15Speaker 10: you have the Johnson and Johnson's that are shelving this medication,
- 52:18Speaker 10: which means that healthcare in the United States.
- 52:21Speaker 7: Needs to change first, right.
- 52:22Speaker 10: It means that we need to start taking a look
- 52:24Speaker 10: at who's funding this innovation and how we're going to
- 52:27Speaker 10: bring some of the smaller players in to make it happen.
- 52:31Speaker 10: Because we can talk about the science of it all
- 52:33Speaker 10: day long, but the reality is the patient doesn't really
- 52:36Speaker 10: care about the science.
- 52:37Speaker 7: They don't care about how the soup is made. They
- 52:39Speaker 7: just simply need it.
- 52:41Speaker 6: Yeah, I appreciate affordability.
- 52:44Speaker 4: Affordability is a big issue, and you know, not only
- 52:49Speaker 4: in the medications, but the diagnostic testing. So you know, payers,
- 52:58Speaker 4: that is our work in market access and reimbursement for
- 53:01Speaker 4: the most part, and proving to payers that they'll see
- 53:07Speaker 4: a return on investment in a product.
- 53:10Speaker 11: Yeah, if I could add to it, I think Ryan
- 53:12Speaker 11: made a very good point.
- 53:13Speaker 9: I love what he says about patient centric because that's
- 53:16Speaker 9: ultimately what we're all here in some way or some form.
- 53:19Speaker 9: It's about the patient. The problem is is that our
- 53:22Speaker 9: system doesn't allow us to truly be patient centric. You know,
- 53:25Speaker 9: when we look at our industry and a new nce
- 53:28Speaker 9: can fully capitalize could be anywhere from a half a
- 53:31Speaker 9: billion to a billion dollars. It's different obviously on the
- 53:35Speaker 9: generic side, but the generic sides get even more complicated,
- 53:38Speaker 9: more like brand because we're now moving into more complex
- 53:40Speaker 9: drugs programs that cost more with greater risk, So we're
- 53:45Speaker 9: even the generic size acting more like brands. I'm going
- 53:48Speaker 9: to say something controversial, especially for somebody who's in the industry,
- 53:51Speaker 9: is we have to change fundamentally a number of things.
- 53:55Speaker 9: We need to change our patent laws. Our patent laws
- 53:57Speaker 9: do not allow for innovation. It does not allow for
- 54:00Speaker 9: companies to invest even on more precise medication because it's
- 54:03Speaker 9: not profitable. We need to get rid of direct to
- 54:07Speaker 9: consumer advertising. If we spent the money and took away
- 54:10Speaker 9: direct to consumer advertising and put it back into what
- 54:13Speaker 9: we should be doing, we could do a lot more
- 54:15Speaker 9: better and in many countries like Europe or in European Union,
- 54:19Speaker 9: you can't do what we do here. So I know
- 54:22Speaker 9: that the people that pull ads on the Super Bowl
- 54:26Speaker 9: would be unhappy with me. But the fact is that
- 54:28Speaker 9: we're not doing things that are patients centric. We have
- 54:32Speaker 9: to find ways to relook at what we're doing to
- 54:36Speaker 9: reincentivize companies to take those projects because they are important
- 54:42Speaker 9: and put them back into mainstream because but that also
- 54:45Speaker 9: means we have to change things on the delivery healthcare
- 54:47Speaker 9: because manufacturers have taken look at manufacturers over the year
- 54:52Speaker 9: have always been the escapegoat, and rightfully so in many cases,
- 54:55Speaker 9: but not all cases. And the industry on the manufacturing
- 54:58Speaker 9: side is not as evil as we're out to be.
- 55:00Speaker 9: There's a lot of other players that are taking a
- 55:02Speaker 9: lot of the profit out that makes it difficult for
- 55:05Speaker 9: manufacturers to continue to invest in development. And as you
- 55:08Speaker 9: see and you see it, you know, when I joined
- 55:10Speaker 9: this industry back in thirty years, the mrks of the
- 55:13Speaker 9: world were the most miyor companies in the United States,
- 55:17Speaker 9: and they did because they were reinvesting twenty six twenty
- 55:20Speaker 9: eight percent of their profit back into R and D.
- 55:23Speaker 9: Now most of these large organizations do not have the
- 55:25Speaker 9: R and D budgets because they've had to reduce it
- 55:27Speaker 9: to create profit, to keep people happy, and they've gone
- 55:30Speaker 9: out to see the cbmos and that's where all the
- 55:32Speaker 9: expertise has gone. And we've got it all backwards again.
- 55:36Speaker 9: So we need to reframe it again, and I think
- 55:39Speaker 9: through that we can actually deliver these type of products
- 55:41Speaker 9: that will add value, that will deliver down to more
- 55:45Speaker 9: subpopulations within individual indication, and that's what we need to
- 55:50Speaker 9: ultimately drive to create better value and outcome. But if
- 55:53Speaker 9: we don't change the system, the system is working against us.
- 55:57Speaker 9: And you know, and we need to give manufacture is
- 56:00Speaker 9: an opportunity to do it right, and we can. But
- 56:02Speaker 9: to do it right, we have to take some of
- 56:04Speaker 9: the risk out of it for us. You know, we
- 56:07Speaker 9: can't invest a half a billion dollars and take twelve
- 56:10Speaker 9: years to get a product and only have five years
- 56:12Speaker 9: to make your capital investment back.
- 56:14Speaker 11: So we have to find a way to create that
- 56:17Speaker 11: new balance. But again, I like what Ryan.
- 56:20Speaker 9: Has said because if we can reset to being patient
- 56:24Speaker 9: centric more, we talk about and we do a lot
- 56:27Speaker 9: of things. We do patient advocacy efforts and we do
- 56:29Speaker 9: around tables, but we're not really doing what I think
- 56:32Speaker 9: Ryan's articulating.
- 56:34Speaker 11: And you know, at the end of the day, when United.
- 56:37Speaker 9: Healthcare is one of the largest most profitable companies in
- 56:40Speaker 9: the United States of America, that tells you're right there
- 56:43Speaker 9: and foremost that the value of where the healthcare dollars
- 56:48Speaker 9: going is not going to the right place. And that's
- 56:50Speaker 9: what we need to change. But fundamentally, this is a
- 56:52Speaker 9: bigger picture than any one of us can do. But
- 56:54Speaker 9: if we all work together in a more integrated and
- 56:58Speaker 9: syndicated way, than all can play a part to give
- 57:00Speaker 9: me better healthcare out better healthcare outcome.
- 57:04Speaker 2: Thank you, Thank you.
- 57:06Speaker 3: I want to jump right in and you jump in
- 57:08Speaker 3: and kind of think about what Scott was going through
- 57:11Speaker 3: and what was coming up in your mind.
- 57:18Speaker 2: I can't hear you. Are you muted? I sure was, Todd.
- 57:24Speaker 2: Can you hear me now? Scott's case?
- 57:27Speaker 6: What?
- 57:28Speaker 8: What's very complex?
- 57:29Speaker 4: You know?
- 57:31Speaker 8: I agree with what everyone is saying here where you
- 57:34Speaker 8: know we need to healthcare should be patient centric. It
- 57:38Speaker 8: should be about the patient, not about a profit. How
- 57:42Speaker 8: do you how do you go about changing that? How
- 57:45Speaker 8: do you how do you do this huge overhaul because
- 57:48Speaker 8: it's so ingrained in our in our system here in
- 57:52Speaker 8: the Western world. I really don't have anything else to add.
- 57:58Speaker 8: I agree with what everyone is saying some very valid
- 58:01Speaker 8: points when it comes to this case.
- 58:05Speaker 3: I was concerned with multi things falling apart, you know,
- 58:10Speaker 3: the effect on his heart, the effect on his lungs,
- 58:12Speaker 3: like things started collapsing. And the only time that I've
- 58:15Speaker 3: ever experienced that personally in my life was one of
- 58:18Speaker 3: my great aunts passing away and she went in because
- 58:21Speaker 3: she was having kidney issues, and then all of a sudden,
- 58:25Speaker 3: everything else started to have apart cut down.
- 58:28Speaker 2: That's scary, That's like, how do you catch up?
- 58:32Speaker 3: How do you you know, what the heck could you
- 58:34Speaker 3: do to help sustain or catch up or prevent.
- 58:38Speaker 2: And so that's definitely something that came up in my mind.
- 58:43Speaker 3: I think, as the consumer of it all the least
- 58:48Speaker 3: experience to the clinical level other than just listening to
- 58:52Speaker 3: all for the last twenty years. But I think that
- 58:56Speaker 3: Symptomatic has a really interesting opportunity here, and that is
- 59:01Speaker 3: to look at season four, look at season five, and
- 59:05Speaker 3: moving forward to really start putting a new spin into this,
- 59:10Speaker 3: which is, how do we get pharmacist insights involved and
- 59:16Speaker 3: how do we let the public that you're missing a
- 59:19Speaker 3: part of your three hundred and sixty degrees of health
- 59:22Speaker 3: care mental health, Like Ryan said, that include the trust
- 59:29Speaker 3: of your medication working at as intended as Becky can
- 59:32Speaker 3: doll into with pharmacogenomics, what's the impact of when everybody
- 59:37Speaker 3: was talking about migraines. My two sisters, Tara and Teresa.
- 59:42Speaker 3: Teresa is actually a nutritionist to register a dietitian. She
- 59:46Speaker 3: was even at a young age twelve years old, was
- 59:50Speaker 3: obsessed with understanding why do I get headaches all the time?
- 59:55Speaker 3: And sure enough, both of my sisters are very sensitive
- 59:58Speaker 3: to glue and live gluten free lives. Now they don't
- 1:00:02Speaker 3: deal with the headaches as often. Every once in a
- 1:00:05Speaker 3: while something comes in. But I immediately started thinking of wow,
- 1:00:09Speaker 3: there are aspects of what people live with day in
- 1:00:13Speaker 3: and day out that we're missing it because of the
- 1:00:16Speaker 3: pressures that we're putting on our physicians to always be right.
- 1:00:21Speaker 2: They're human beings.
- 1:00:22Speaker 3: And that they need more support and they need to
- 1:00:26Speaker 3: take the treatment and kick it off to their pharmacists
- 1:00:29Speaker 3: to dial in and really give them another opportunity to
- 1:00:34Speaker 3: having to see thirty or forty patients a day, No
- 1:00:37Speaker 3: wonder these poor people, Scott and Jose, the rest of
- 1:00:41Speaker 3: them are overlooked because of how the healthcare systems just
- 1:00:46Speaker 3: to churn and burn and churn and churn and churn
- 1:00:49Speaker 3: and let's just get it, get it, go, go go. No,
- 1:00:51Speaker 3: it's time to slow down. One thing symptomatic has taught
- 1:00:54Speaker 3: me is to slow down and to take time to listen.
- 1:00:59Speaker 3: I'm not a clinician, but if I would have sat
- 1:01:01Speaker 3: with you know, Mila Case twenty two, Scott, Kelly, Jose,
- 1:01:07Speaker 3: if I would have sat with any of them, I
- 1:01:09Speaker 3: would have taken time to listen. If one thing I've
- 1:01:12Speaker 3: learned in sixteen years of podcasting is definitely listening to
- 1:01:16Speaker 3: some incredibly intelligent people like yourselves. I'm I'm blown away
- 1:01:22Speaker 3: tonight by how well each of you leveraged the expertise
- 1:01:27Speaker 3: that you have in the verticals that you have, which
- 1:01:29Speaker 3: tells me that more collaboration for patients, the better of
- 1:01:33Speaker 3: giving our nutritionists and our pharmacists and our nurses and
- 1:01:37Speaker 3: our physicians and being able to take some of the
- 1:01:40Speaker 3: pressures off of each other. I can't wait to work
- 1:01:43Speaker 3: on pediatric cases. Shout out to doctor Jenna Quinn, who's
- 1:01:47Speaker 3: on the Pharmacy Podcast Network as our pediatric expert dialing
- 1:01:51Speaker 3: into Geriatrics, dialing into Dementia. A shout out to the
- 1:01:54Speaker 3: Symptomatic team. We want you to leverage our pharmacy network
- 1:01:59Speaker 3: and it's more than just a pharmacist, as you can
- 1:02:02Speaker 3: see tonight with Steven Beckman and and Ryan digging into epidemiology,
- 1:02:08Speaker 3: Ryan Paul and and the the quality that you've all
- 1:02:11Speaker 3: brought tonight, and in closing, I just want to say
- 1:02:15Speaker 3: thank you Becky for being the first one to respond
- 1:02:17Speaker 3: to the request to participate inumatic tonight and from there.
- 1:02:26Speaker 4: But I have a bad habit of watching mysteries.
- 1:02:32Speaker 7: We're just we're just getting warmed up. Todd our number two.
- 1:02:36Speaker 3: Listen Joe talking about Joe Rugan where we podcast for
- 1:02:41Speaker 3: four hours. We're trying to stay in the our window.
- 1:02:46Speaker 11: But hey, look at town. You said something was really
- 1:02:48Speaker 11: important and that we all have to listen more.
- 1:02:51Speaker 12: You know.
- 1:02:52Speaker 9: I'm actually starting to write a book and I wrote
- 1:02:55Speaker 9: the four today and the first thing because I came
- 1:02:57Speaker 9: into my head was the most success whole thing I've
- 1:03:00Speaker 9: learned in my business to be successful in businesses to
- 1:03:03Speaker 9: listen first, Less is more sometimes, But we need, but
- 1:03:08Speaker 9: we need to give the pharmacists. I was on with
- 1:03:10Speaker 9: Walgreen's team just yesterday in our discussions, and the first
- 1:03:14Speaker 9: thing they said is, we don't actually have time to
- 1:03:17Speaker 9: talk to patients independent pharmacists. Obviously, that's been their their
- 1:03:22Speaker 9: core essence and they and they stick to it and
- 1:03:25Speaker 9: they still they still deliver it more. But at the
- 1:03:27Speaker 9: same time, it's hard for them to keep a business profitable.
- 1:03:31Speaker 9: So we have to find a way to actually deliver
- 1:03:33Speaker 9: what everybody said on the phone and pull it all
- 1:03:36Speaker 9: together in a more comprehensive way.
- 1:03:38Speaker 11: And thanks, I learned a lot tonight, guys, so appreciate
- 1:03:42Speaker 11: hearing from all of you.
- 1:03:43Speaker 3: Thank Yeah, heck yea Mark have fun having you in
- 1:03:47Speaker 3: this and just understanding from your perspective. But you listen
- 1:03:53Speaker 3: and you dialogue with the future of pharmacy too. I'm
- 1:03:55Speaker 3: not sure if you told anybody that.
- 1:03:58Speaker 5: Yeah, getting to teach our student pharmacists and you know,
- 1:04:02Speaker 5: other health care professions too, whether it's a pain fellowship
- 1:04:05Speaker 5: or other health science as schools.
- 1:04:07Speaker 6: It's uh, it's thrilling, you know, to see the minds
- 1:04:11Speaker 6: that are you know.
- 1:04:12Speaker 5: Innately we start out more listening. Usually folks stay away
- 1:04:18Speaker 5: for class.
- 1:04:18Speaker 6: Usually you know, I'm.
- 1:04:20Speaker 5: Teaching about illegal drugs or something that's a no brainer,
- 1:04:22Speaker 5: but you know, impacting the future, it's like you get
- 1:04:27Speaker 5: you know, thousands, tens of thousands, if not hundreds of
- 1:04:29Speaker 5: thousands of patients help by impacting the future of health
- 1:04:33Speaker 5: care really too, the the you know something that something
- 1:04:38Speaker 5: resonated with me. It was like forty ish minutes ago,
- 1:04:40Speaker 5: I believe doctor Becky said something and what I translated
- 1:04:43Speaker 5: to because you definite didn't say this, my apologies, was like.
- 1:04:46Speaker 6: Chicken or the egg.
- 1:04:48Speaker 5: And when it comes to medications for treatments, you know
- 1:04:51Speaker 5: which which ones at fault? Like in some of these
- 1:04:54Speaker 5: cases that that we run the edge of our seats
- 1:04:56Speaker 5: for and symptomatic it's like, you know, we obviously had
- 1:04:59Speaker 5: the one I think was Kelly with you know, the
- 1:05:02Speaker 5: medicines actually have fault, you know, like chicken out of
- 1:05:04Speaker 5: the egg, which one we got here? I've had cases,
- 1:05:06Speaker 5: you know, pain management it's like the gateway of gateways
- 1:05:09Speaker 5: because the problem isn't always pain. Boy, it sucks, but
- 1:05:13Speaker 5: the problem is probably something else causing it, right, And
- 1:05:16Speaker 5: we see this all the almost all the time in
- 1:05:18Speaker 5: pain management, where you know you have patient with diabetes,
- 1:05:21Speaker 5: and then all of a sudden, Hey, I think I
- 1:05:23Speaker 5: have peripheral diabetic neuropathy because I saw the ad that
- 1:05:26Speaker 5: Stephen talked about that was made legal fifty years ago
- 1:05:29Speaker 5: in our country, and I think I knew that drug.
- 1:05:31Speaker 5: And you're like, WHOA, let's just skip past the next three.
- 1:05:34Speaker 6: Months of trying to figure out what you got going on.
- 1:05:36Speaker 5: Like it's chicken at the egg, you know, and you
- 1:05:40Speaker 5: know in that case, maybe it's one of the medications
- 1:05:42Speaker 5: to treat your diabetes, might affect your vitamin B twelve absorption.
- 1:05:46Speaker 5: And then two other panelists here are going out of
- 1:05:48Speaker 5: their minds of like, that's so simple. We learned it
- 1:05:50Speaker 5: the first year of pharmacy school. That's where we help.
- 1:05:53Speaker 5: That's where pharmacists come to the table. It's oftentimes what's
- 1:05:56Speaker 5: the most common sense to all of us because that's
- 1:05:59Speaker 5: what our training is. You know, I'm a pharmacist. Here
- 1:06:02Speaker 5: us roar, that's what symptomatic needs. Yes, absolutely, all attached
- 1:06:09Speaker 5: or I would you know?
- 1:06:09Speaker 6: I would?
- 1:06:12Speaker 2: Well, this has been awesome. This has been our first
- 1:06:15Speaker 2: go at this.
- 1:06:15Speaker 3: This will not be our last Symptomatic Medical Mystery podcast
- 1:06:20Speaker 3: by the iHeartMedia team the Ruby division. A shout out
- 1:06:24Speaker 3: to your team, a shout out to Ethan and Jody
- 1:06:28Speaker 3: and Amber who I've been working with in the inside
- 1:06:31Speaker 3: of the Ruby iHeart team. And thank you to my panelists.
- 1:06:35Speaker 3: Thank you to each of you for taking the reins
- 1:06:38Speaker 3: to be my guinea pigs and be available to us
- 1:06:42Speaker 3: tonight to throw you out there into the into the
- 1:06:45Speaker 3: podcast wolves to give us your assessment of each of
- 1:06:49Speaker 3: these cases.
- 1:06:50Speaker 2: I really appreciate it. Thanks, thank you, thanks last, thank
- 1:06:55Speaker 2: you all.
- 1:06:57Speaker 9: Well.
- 1:06:57Speaker 2: Listen.
- 1:06:58Speaker 3: Listen to all symptomatic by going to iHeartRadio. That's iHeart
- 1:07:02Speaker 3: dot com and register and look up symptomatic really on
- 1:07:07Speaker 3: any of your podcast apps. Subscribe to Pharmacy Podcast Network
- 1:07:11Speaker 3: to tie into the leading pharmacists in healthcare, and that's
- 1:07:16Speaker 3: right here on the Pharmacy Podcast Network.
- 1:07:18Speaker 2: We'll talk to you next time.